Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Neonc Technologies, Inc.
Var2 Pharmaceuticals
Degron Therapeutics Co.
LigaChem Biosciences, Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Apollomics Inc.
Bayer
Shandong Cancer Hospital and Institute
Cedars-Sinai Medical Center
NGM Biopharmaceuticals, Inc
Prelude Therapeutics
ABM Therapeutics Corporation
Cedars-Sinai Medical Center
Quadriga Biosciences, Inc.
Celgene
Hospices Civils de Lyon
AbbVie
Celgene
Tocagen Inc.
Celldex Therapeutics
Stanford University
Icahn School of Medicine at Mount Sinai
Stanford University
AbbVie
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Pharmacyclics LLC.
Siemens Molecular Imaging